Physician profile
S K Brown
NPI 1336118637
$21,822.29
in general payments reported to CMS, 2019-2025
15 companies · $14.30 in 2025
The $14.30 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.40 · 2021: $15K · 2022: $5,622 · 2023: $222 · 2024: $485 · 2025: $14.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20,452.78 | 2019-2022 | |
| Merz North America, INC. | $434.91 | 2021-2023 | |
| Abbvie INC. | $271.87 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.78 | 2021-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.12 | 2021-2022 | |
| Qol Medical, LLC | $99.97 | 2024 | Sucraid |
| Ardelyx, INC. | $79.92 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $78.73 | 2021-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $36.20 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $34.35 | 2021 | |
| Braintree Laboratories, INC. | $28.96 | 2021-2024 | Suflave |
| Lilly USA, LLC | $23.53 | 2024 | Zepbound |
| Merck Sharp & Dohme LLC | $22.42 | 2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.06 | 2023 | Cyltezo |
| Celltrion USA INC. | $13.69 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw S Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.